There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jasper Therapeutics (JSPR – Research Report) and ...

Jasper expects to report data around mid-year 2025 from 4 cohorts: the 240mg single dose cohort (4 additional patients), 240mg Q8W cohort (8 patients), 240mg followed by 180mg Q8W cohort (8 patients), ...

Live webcasts of the presentations will be available on the News & Events – Events page of Jasper's Investor Relations website. An archived replay of each presentation will be available on ...

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update Jasper Therapeutics, Inc. Thu, Feb 27, 2025, 5:00 AM 11 min read ...

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing novel therapies for hematopoietic stem cell transplantation and mast cell-mediated diseases.

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Free Report) have earned an average rating of “Buy” from the eleven analysts that are covering the company, Marketbeat reports.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company focused on developing novel therapies for hematopoietic stem cell transplantation and mast cell-mediated diseases. The ...

REDWOOD CITY, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Jasper Therapeutics (NasdaqCM:JSPR) with a Buy recommendation. Analyst Price Forecast Suggests 1,084.43% Upside As of January 29 ...